Immunotherapeutic Approach of Experimental Brain Tumor with a Corpuscular Antigen
Swapna Chaudhuri*1, Soven Kumar Gangopaddhyay1
Susobhan Sarkar1 and Samaresh Chaudhuri2
1Cellular & Molecular Immunology Lab, Department of Physiology
University Collage of Medicine, 244B, A.J.C. Bose Road, Kolkata – 700020
2Section of Immunology, Department of Haematology
School of Tropical Medicine, C.R. Avenue, Kolkata – 700073
ABSTRACT
Young Druckrey rats of both sexes ageing 5-10 days were injected with fractionated and acute doses of N-N’ ethylnitrosourea intraperitoneally. This required an optimum period of 6-8 months to develop brain tumor with a mean survival of 190 days. Sheep erythrocytes (SRBC) when administered (ip. 7% PCV/V, 0.5 ml) in a group of animals at the end of seventh month of ENU administration, resulted in significant increase in the mean survival time (>350 days). Studies conducted for growth kinetics pattern with proliferation index and fluorochrome (HO – 33342) uptake techniques at the tissue culture level exhibited a regulatory inhibition of the cell excised from the tumor susceptible area of brain of SRBC treated animals compared to those of untreated tumor controls. Further probe into the mechanisms involving immunological investigations at the cellular level in these animals indicated an augmented and potentiated cell mediated immune response (CMI) as evidenced by enhanced spontaneous rosette forming capacity and cytotoxic activity of lymphocytes and neutrophil (PMN) mediated phagocytosis respectively. Moreover histological studies demonstrated reversion of neoplastic glial features to normal glial features in SRBC-treated tumor bearing animals. The observations suggest that SRBC down regulates malignant growth pattern of experimental brain tumors either by an immunologically enhanced killing of tumor cells and/or by directly inhibiting the tumor growth possibly via a stimulated cytokine network.
INTRODUCTION
Treatment of brain tumor presents unique challenge because of unique aspects of their biology and anatomic site, and their overall poor response to current therapeutic approaches involving surgery. . . . .
REFERENCES
BALKWILL FR. 1989. In: Cytokines in cancer therapy. 8p. Oxford University Press, Oxford.
BARTEL AL, HEILBROON YD, SHIFFER J. 1973. Extensive resection of primary malignant tumor of the left cerebral hemisphere. Surgical Neurology 1: 337-342.
BARTH RF. 1998. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F89, RG2 (D74), RT-2 and CNS-1 gliomas. Journal of Neurooncology 36(1): 91-102.
BEGUM Z, SARKAR S, MUKHERJEE J, GHOSH A, CHAUDHURI S, CHAUDHURI S. 2003. Evaluation of antitumor property of specific and non-specific BRMs in experimental glioma by assessing the microglial cell function and phenotypic modulations. Cancer Biology and Therapy 2(IV): 356-363.
BERNARD AL, TRAN HC, BOUMSELL L. 1987. Three different erythrocyte surface molecules are required for spontaneous T cell rosette formation. Journal of Immunology 139(1): 18-23.
BERGQUIST BJ, MAHALEY MS JR, STEINBOOK P, DUDKA L. 1980. Treatment of brain tumor with BCG cell wall preparation. Surgical Neurology 13(3): 197-201.
BODMER S, STROMMER K, FREI K. 1989. Immunosupression and transforming growth factor beta 2. Journal of Immunology 143: 3322-29.
BRADLE M. 1966. Immune control of the brain. In: Immunoneurology (eds Chofflon M & Steinman L) p. 153-167. Springer-Verlaq, Amsterdam, New York.
CHAUDHURI S, SINHA A, SENGUPTA A, CHAUDHURI S. 1991. Sheep erythrocytes provide metabolic triggers for tumor phagocytosis in polymorphonuclear neutrophils: A possible mechanism for tumor inhibition in mice. Biochemistry International 23(20): 231-241.
CHAUDHURI S, DUTTA SK, ROY N, GANGOPADHAYAY SK, CHAUDHURI S. 1993. Immunomodulation and Ia variability in dendritic lymph cells: radiobinding immunoassay versus immune response study. Biochemistry International 30(30): 471-477.
CHAUDHURI S, GANGULY S, GHOSH SN, DUTTA S, SARKAR S, BEGUM Z, ROY RU, BHATTACHARYA MK, DUTTA SK, CHAUDHURI S. 2000. Immunological insurgence during intracranial tumor development: Cellular immunity in astrocytoma patients. Journal of Physiology & Appllied Science 54(3): 118-129.
CLEMENS MJ. 1991. Cytokines. p. 103. Bioscientific Publications, Oxford.
DENNING SM, DUSTIN ML, SPRINGER TA, SINGER KH, HAYNES BF. 1988. Purified lymphocyte function associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway. Journal of Immunology 141 (9): 2980-85.
DIENGDOH JV, BOOTH AE. 1976. Post-irradiation necrosis of the temporal lobe presenting as a glioma. Journal of Neurosurgery 44(6): 732-734.
DIX AR, BROOKS WH, ROSZMAN TL, MORFORD LA. 1999. Immune defects observed in patients with primary malignant brain tumors. Journal of Neuroimmunology 100(1-2): 216-232.
DRUCKREY H, IVANCOVIC S, PREUSSMAN R. 1966. Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats. Nature 210: 1378-79.
DUSTIN ML, SANDERS ME, SHAW S, SPRINGER TA. 1987. Purified lymphocyte function associated antigen-3 binds to CD2 and mediates T lymphocyte adhesion. Journal of Experimental Medicine 165: 677-692.
EBERT EC. 1985. Sheep red blood cells enhance Tlymphocytes proliferation. Clincal Immunology and Immunopathology 37(2): 203-212.
ENDO Y, MATSUSHIMA K, OPPENHEIN J. 1986. Mechanism of in vitro antitumor effects of interleukin 1 (IL-1). Immunobiology 172: 316-322.
GILLESPIE GY, MAHALEY MS. 1995. Biological response modifier therapies for patients with malignant gliomas: In: Neuro-oncology (eds GT Thomas) p. 242-281. Churchill Livingstone, New York, London.
GLANTZ MJ, KIM L, CHOY H, AKERLEY W. 1999. Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncology (Huntinat) 10: 78-82.
GUTIERREZ M, FORSTER FI, MC CONNELL SA, CASSIDY JP, POLLOCK JM, BRYSON DG. 1999. The detection of CD2+, CD4+, CD8+ and WC1+ T-lymphocytes B cells and macrophages in fixed and paraffin embedded bovine tissue using a range of antigen recovery and amplification techniques. Vetinary Immunology and Immunopathology 71(3-4): 321-334.
HISHII M, NITTA T, ISHIDA H. 1995. Human glioma derieved interleukin-10 inhibits antitumor immune response in vitro. Journal of Neurosurgery 37: 1160-66.
HOSHINO T, BARKER M, WILSON CB, BOLDREY EB, FEWER D. 1972. Cell kinetics of human gliomas. Journal of Neurosurgery 49: 13-21.
HOSHINO T. 1984. Commentry of the biology and growth kinetics of low grade and high grade gliomas. Journal of Neurosurgery 61: 895-900.
HUDSON L, HAY FC. 1989. Cell dynamics in vivo. In: Practical Immunology. Blackwell Scientific Publications. p. 182-206. Oxford, London, Edinburg, Boston, Melbourne.
HUNIG T. 1985. The cell surface molecule recognized by the erythrocyte receptor of T lymphocyte. Journal of Experimental Medicine 162: 890-901.
HUNIG T, MITRACHT R, TIEFENTHALER G, KOHLER C, MIYASAKA M. 1986. The cell surface molecule binding to the ‘erythrocyte receptor’ of T-lymphocytes, cellular distribution, purification to homogeneity and biochemical properties. European Journal Immunology 16(12): 1615-1621.
HUNIG T, TIEFENTHALER G, MITRACHT R, KHOLER C, LOTTSPEICH F, MEUER S. 1987. The erythrocyte receptor of T-lymphocytes and T-11 target structure (T11TS): Complementary cell interaction molecules involved in T-cell activation. Behring Inst Mitt. 81: 31-40.
ISHIZAWA A. 1981. Immunotherapy for malignant glioma. Neurologica Medico – Chirugica (Tokyo). p. 179-191.
JACOBS SK, WILSON DL, KOANBLITH PL, GRIMM EA. 1986. Interleukin-2 or autologous lymphokine activated killer treatment of malignant glioma: Phase I trial. Cancer Research 46: 2102-04.
KOESTNER A, SWENBERG JA, WECHSLER W. 1971. Transplacental production with ethylnitrosourea of neoplasms of the nervous system in SpragueDawley rats. American Medical Journal of Pathology 63: 37-39.
KOVASU S, LAWTON T, NOVICK D, REENV MA, SILICIANO RF, WALLNER BP, REINHERZ EL. 1990. Role of interaction of CD2 molecule with lymphocyte function associated antigen-3 in T-cell recognition of normal antigen. Proceedings of National Academy of Science USA 87: 2603-2607.
KRENSKY AM, ROBBINS E, SPRINGER TA, BURAKOFF SJ. 1984. LFA-1, LFA-2 and LFA-3 antigens are involved in CTL-target conjugation. Journal of Immunology 132: 2180-82.
KUPPNER MC, HAMOU MF, SAWAMURA Y. 1989. Inhibition of lymphocyte functions by glioblastoma - derieved transforming growth factor beta 2. Journal of Neurosurgery 71: 211-217.
LANTOS PL. 1993. Chemical induction of tumors in nervous system. In: Neurooncology (eds GT Thomas) p. 85-107. Churchill Livingstone, New York. London.
LANTOS PL, VANDENBERG SR, KLEIHUES P. 1997. Tumors of the nervous system. In: Greenfield’s Neuropathology, (eds David I, Graham & P Lantos) 6th ed. 2: 583. Arnold, London, Sydney, Auckland.
LAW S, MAITI D, PALIT A, MAJUMDAR D, BASU K, CHAUDHURI S, CHAUDHURI S. 2001. Facilitation of functional compartmentalization of bone marrow cells in leukemia mice by biological response modifiers: an immunotherapeutic approach. Immunology Letters 76: 145-152.
LEVY DE. 1988. Interferon: To-day and To-morrow. Mediscript. London.
MAXWELL M, GALANOPOUIOS T, NEVILLE-GOLDEN. 1992. Effect of the expression of the transforming growth factor beta 2 in primary human glioblastomas on immunosuppression and loss of immunosurveillance. Journal of Neurosurgery 76: 199-280.
MEUER SC, HUSSEY RE, FABBI M, FOX D, ACUTO O, FITZGERALD KA, HODGDON JC, PROTENTIS JP, SCHLOSSMAN SF, REINHERZ EL. 1984. An alternative pathway of T-cell activation: a functional role for the 50 KD T11 sheep erythrocyte receptor protein. Cell 36: 897-906.
MEUER SC, ROUX MV, SCHRAVEN B. 1989. The alternative pathway of T-cell activation: biology, pathophysiology and perspective for immunopharmacology. Clincal Immunology and Immunopathology 50: 133-139.
NAKAGAKI M, BRUNHART G, KEMPERT, CAVENESS WF. 1976. Monkey brain damage from radiation in the therapeutic range. Journal of Neurosurgery 44: 3-11.
NAKAGAWA Y, KIRAKAWA K, UEADA S, SUZUKI K, FUKUMA S, KISHIDA T, IMANISHI J, AMAGAI T. 1985. Local administration of interferon for malignant brain tumors. Cancer Treatment Reports 67: 833-833.
NIIAZOVA OP, OSIPOVA SO, BADALOVA NS, DEKHKANKHODZHAEVA NA. Early and late E-rosette forming neutrophils in persistent lambliasis. Med ical Parazitology (Moskow) 1: 43-44.
OGASAWARA H, KUSUV K, TAKASAKI S. 1995. Role of terminal galactose residues in N-linked sugar chains of sheep erythrocyte membrane glycoproteins in rosette formation with T lymphocytes. Immunology Letters 48: 35-38.
PALMA L, DI LOVENZO N, GUIDETTI B. 1978. Lymphocyte infiltrates in primary glioblastomas and residal gliomas. Incidence, fate and relevance to prognosis in 288 operated cases. Journal of Neurosurgery 49: 854-861.
PANG GT, WIGGINS PM, WILSON JD. 1976. Nature of the union between sheep red blood cells and T lymphocytes. International Archives Allergy and Applied Immunology 51: 751-756.
POLLACK IF, OKADA H, CHAMBERS WH. 2000. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Seminar in Pediatrics Neurology 7(2): 131-143.
RAHA SK, DEY SK, ROY SK, CHAUDHURI S, CHAKRABORTY SL. 1990. Antitumor activity of L-Asparaginase from Cylindrocarpon obstutisporum MB 10 and its effects on the immune system. Biochemistry International 21(6): 987-1000.
ROSZMAN TL, BROOKS WH. 1990. Immunobiology of primary intracranial tumors III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumors. Clinical and Experimental Immunology 39: 395-402.
ROY RU, SARKAR S, DUTTACHAUDHURI M, DUTTA SK, CHAUDHURI S, CHAUDHURI S. 1997. Antigen presenting capacity of mononuclear phagocytes in experimental leukemia and in patients with hematological malignancies in India. Journal Hematology & Blood Transfusion 15(1): 33.
SAMUEL C. 1987. Mechanism of interferon actions. (ed LM Pfeffer) 111p. CRC Press Inc., Florida.
SELMAJ K. 1996. Pathophysiology of the blood-brain barrier. In: Immunoneurology (eds M Chofflon & L Steinman) p. 175-191. Springer –Verlaq, Amsterdam, New York.
SELVARAJ P, PLUNKETT ML, DUSTIN M, SANDERS ME, SHAW S, SPRINGER TA. 1987. The lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 326: 400-403.
SEMNANI RT, NUTMAN TB, HOCHMAN P, SHAW S, VAN SEVENTER GA. 1994. Co-stimulation by purified intercellular adhesion molecule 1 and lymphocyte function associated antigen-3 induces distinct proliferation, cytokine and cell surface antigen profiles in human “naïve” and “memory” CD4+ T-cells. Journal of Experimental Medicine 180: 2125-35.
SILICIANO RF, PRATT JC, SCHMIDT RE, RITZ J, REINHERZ EL. 1985. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature 317: 428-430.
SPRINGER TA, DUSTIN ML, KISHIMOTO TK, MARTIN SD. 1987. The lymphocyte function associated LFA-1, CD2 and LFA-3 molecules. Cell adhesion receptors of the immune system. Annual Review of Immunology 5: 223-252.
STARK GR. 1988. The regulation of gene expression by interferons. Today and Tomorrow. Mediscript. 4p. London.
STEEL GG. 1980. Growth kinetics of brain tumors. In: Brain tumors: Scientific Basis, clinical investigations and current therapy. p. 10-20. Butterworths, London.
SUN ZJ, DOTSCH V, KIM M LI J, REINHERZ EL, WAGNER G. 1999. Functional glycan–free adhesion domain of human cell surface receptor CD58: design, production and NMR studies. European Molecular Biology Organisation 18: 2941-49.
TIEFENTHALER G, DUSTIN ML, SPRINGER TA, HUNIG T. 1987. Serological cross reactivity of T11 target structure and lymphocyte function associated antigen-3. Evidence for structural homology of the sheep and human ligands of CD2. Journal of Experimental Medicine 139(8): 2696-2701.
WALLENER BP, FREY AZ, TIZARD R, MATTALIANS RJ, HESSION C, SANDERS ME, DUSTIN ML, SPRINGER T. 1987. Primary structure of lymphocyte associated antigen3 (LFA-3). The ligands of the T lymphocytes CD2 glycoprotein. Journal of Experimental Medicine 166: 923-932.
WELLER RO, ENGELHARDT B, PHILLIPS MJ. 1996. Lymphocytes targeting of the central nervous system: a review of afferent and efferent CNS immune pathways. Brain Pathology 6(3): 275-288.
WILKINSON M, MORIS AG. 1984. Role of the E-receptor in interferon-gamma expression: Sheep erythrocytes augment interferon-gamma production by human lymphocytes. Cell Immunology 86 (1): 109-117.
WINGREN AG, PARRA E, VARGA M, KALLAND T, SJOGREN HO, HEDLUM G, DOHLSTEN M. 1995. T-cell activation pathways: B7, LFA-3 and ICAM-1 shape unique T cell profiles. Critical Review of Immunology 15: 109-117.
